ZS oncology experts Christina Corridon and Pavan Anne discuss their recent survey of physicians, payers, and pharmacy managers regarding attitudes toward biosimilars
Most health plans are covering at least one of the two biosimilar products currently on the market, according to new research by the strategic advisory company Avalere.
Four in five oncologists have tried Zarxio/Granix, according to a new survey by ZS Associates. Of those, 48 percent prescribe the reference biologic more than the biosimilar, 43 percent prescribe the biosimilar more, and 8 percent have equal prescriptions for the reference biologic and the biosimilar.
At its core, “Customer experience,” or CX, is shorthand for the relationship between a customer and a company, even if that company is removed from the point of sale. The CX relationship should stretch across all touchpoints both physical and virtual and all media in between. Today’s customers expect companies to know and understand them, creating a seamless experience across the entire customer-company relationship.
Just 27 percent of physicians say they find pharma websites to be a credible source of professional information, according to a recent survey by Manhattan Research.
The Fishawack Group of Companies – one of the largest independent medical communications organizations – acquired the Carling Group of Companies, based in San Diego, Calif.
Fingerpaint named a longtime creative duo as the new leaders of the agency’s creative team. Katie Beller and Andy Spitzer are based in the agency’s headquarters in Saratoga Springs, New York.
Keri Hettel was made senior VP, Analytics and Strategy, and Brandon Ashcraft was promoted to senior VP, Operations, at Razorfish Health.
UDG Healthcare acquired Cambridge BioMarketing, a U.S.-based healthcare communications business, for a total consideration of up to $35 million.
Discovery Worldwide appointed Rico Ricketson as head of client services.